• X-BIOTIX IS A BIOTECHNOLOGY COMPANY

    specializing in the development of novel small molecule antibiotic scaffolds for multi-drug resistant (MDR) gram-negative pathogens to address the urgent and growing global threat of antibiotic resistance. The company is applying a multi-target strategy to generate a pipeline of effective antibiotics with inhibitory activity against a wide range of biological targets in essential pathways of gram-negative bacterial cells and which are also predicted to defeat known antibiotic resistance mechanisms.

OUR APPROACH

X-Biotix is focused on the discovery of novel small molecule antibiotics that target resistant Gram-negative bacteria. The scientific foundation for X-Biotix Therapeutics is based on screening novel targets using chemical matter from DNA-encoded screening libraries containing hundreds of billions of molecules. The company employs a unique combination of proprietary biological and genetic tools, library screening, and its deep knowledge of antibacterial medicinal chemistry to discover and advance novel tractable chemical matter into optimized antibacterial molecules that show selective activity against all or specific gram-negative ESKAPE pathogens and which can be further developed into drug candidates. Priority is given to the screening of multiple targets that have the potential to be inhibited by one compound (dual target inhibition).  So far, this approach has led to a pipeline of first-in-class programs directed against a range of Gram-negative targets with different mechanisms of action.

BOARD OF DIRECTORS

Steve T. Issacs

Chairman, Board of Directors

NEWS

© 2021 X-Biotix Therapeutics, Inc. • All rights reserved.

Mr. Isaacs has served as the Chairman of X-Biotix’s Board of Directors since April 2018. He has more than 40 years of corporate leadership and scientific management experience within the biopharmaceutical sector, and has served as the Chairman, President & CEO of Aduro Biotech, Inc. since 2008. Prior to Aduro, Steve founded Cerus Corporation in 1991, a biomedical products company commercializing the Intercept Blood Systems. The Intercept systems are now globally available and used to prevent a variety of diseases from blood transfusion. He served as President and Chief Executive Officer of Cerus from 1991 to 2004. Prior to Cerus, Steve founded and served as Chief Executive Officer and President of HRI Associates and HRI Research, both biotechnology companies focusing on research and development in various areas. He held a non-teaching faculty position in the Department of Chemistry at the University of California Berkeley from 1978 to 1986. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.

In addition to leading multiple biotechnology companies, Steve has spent considerable time on the African continent working on various non-profit activities. With his family, he founded “A Better Education” (ABE) Club, which provides educational opportunities, microfinance training and healthcare for remote villagers in the south of Kenya.  More recently, he founded the Alliance for Global Health and Science with the Department of Public Health at UC Berkeley, which undertakes capacity building at universities and medical schools in Uganda and Zimbabwe.  He also established the Immunotherapeutics and Vaccine Research Initiative at UC Berkeley, which is an Aduro-sponsored campus-wide organization to promote immunological research for cancer and infectious disease, and has been widely recognized in the industry as an innovator and leader, forging deep ties between biotech and academia with the goal of discovering breakthrough technologies to make an impact on global health. Steve holds an undergraduate degree in biochemistry from the University of California at Berkeley, where he also pursued Ph.D. studies in organic chemistry.